{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nuechterlein N"],"funding":["National Institute of Neurological Disorders and Stroke","National Science Foundation Graduate Research Fellowship Program","NINDS NIH HHS","NCI NIH HHS"],"pagination":["41"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11390787"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["148(1)"],"pubmed_abstract":["Oligodendroglioma, IDH-mutant and 1p/19q-codeleted has highly variable outcomes that are strongly influenced by patient age. The distribution of oligodendroglioma age is non-Gaussian and reportedly bimodal, which motivated our investigation of age-associated molecular alterations that may drive poorer outcomes. We found that elevated HOXD12 expression was associated with both older patient age and shorter survival in the TCGA (FDR < 0.01, FDR = 1e-5) and the CGGA (p = 0.03, p < 1e-3). HOXD12 gene body hypermethylation was associated with older age, higher WHO grade, and shorter survival in the TCGA (p < 1e-6, p < 0.001, p < 1e-3) and with older age and higher WHO grade in Capper et al. (p < 0.002, p = 0.014). In the TCGA, HOXD12 gene body hypermethylation and elevated expression were indep"],"journal":["Acta neuropathologica"],"pubmed_title":["HOXD12 defines an age-related aggressive subtype of oligodendroglioma."],"pmcid":["PMC11390787"],"funding_grant_id":["R35 CA253119","DGE-1762114","Intramural Research Program"],"pubmed_authors":["Gilbert MR","McGranahan T","Rajan S","Nuechterlein N","Shelbourn A","Aldape K","Shapiro LG","Holland EC","Ha V","Cimino S","Arora S","Cimino PJ"],"additional_accession":[]},"is_claimable":false,"name":"HOXD12 defines an age-related aggressive subtype of oligodendroglioma.","description":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted has highly variable outcomes that are strongly influenced by patient age. The distribution of oligodendroglioma age is non-Gaussian and reportedly bimodal, which motivated our investigation of age-associated molecular alterations that may drive poorer outcomes. We found that elevated HOXD12 expression was associated with both older patient age and shorter survival in the TCGA (FDR < 0.01, FDR = 1e-5) and the CGGA (p = 0.03, p < 1e-3). HOXD12 gene body hypermethylation was associated with older age, higher WHO grade, and shorter survival in the TCGA (p < 1e-6, p < 0.001, p < 1e-3) and with older age and higher WHO grade in Capper et al. (p < 0.002, p = 0.014). In the TCGA, HOXD12 gene body hypermethylation and elevated expression were indep","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-02T23:22:34.551Z","creation":"2025-04-04T07:41:06.93Z"},"accession":"S-EPMC11390787","cross_references":{"pubmed":["39259414"],"doi":["10.1007/s00401-024-02802-1"]}}